Results 71 to 80 of about 557 (132)

Expanding the Treat-to-Target Toolbox for Obesity and Diabetes Care. [PDF]

N Engl J Med
Hales CM.
europepmc   +1 more source

Peptide Hormones in Appetite Regulation: A Complex Network. [PDF]

Pharmaceuticals (Basel)
Abdollahi S, Adam H, Al Musaimi O.
europepmc   +1 more source

Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy? [PDF]

Curr Hypertens Rep
Kylies D, Dreher L, Wenzel UO.
europepmc   +1 more source

Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review. [PDF]

World J Clin Pediatr
Fuentes-Mendoza JM, Concepción-Zavaleta MJ, Dongo-Dueñas LG, Jara-Pianto JMJ, Sierra-Martel JA, Medina-Angulo CA, Virú-Flores HM, Mendoza-Godoy JJ, Zavaleta-Gutiérrez FE, Paz-Ibarra J.   +9 more
europepmc   +1 more source

Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies. [PDF]

Front Endocrinol (Lausanne)
Alhazmi A, le Roux CW.
europepmc   +1 more source

Anti-Obesity Drugs: The Rising Significance of GLP-1Agonist, Tirzepatide. [PDF]

J Midlife Health
Agrawal PK, Garg R.
europepmc   +1 more source

Bariatric Surgery in the Era of GLP1RA: A Narrative Review. [PDF]

Adv Ther
Muhundan M, Dash S.
europepmc   +1 more source

Advances in Cyclic Peptides Targeting G Protein-Coupled Receptors. [PDF]

Chembiochem
Zhou Y, Li N, Zheng JS.
europepmc   +1 more source

Pharmacological management of obesity: Current landscape and emerging therapies. [PDF]

Indian J Pharmacol
Atal S, Agrawal C, Gupta R, Sadasivam B.
europepmc   +1 more source

The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies. [PDF]

Biosci Rep
Patil M, Piccinini F, Johnstone EKM, Casari I, Falasca M.   +4 more
europepmc   +1 more source